Addressing the Corneal Nerves in DED Care - Report - MDSpire

Addressing the Corneal Nerves in DED Care

  • By

  • Caroline Watson, MD

  • April 1, 2025

  • 10 min

Share

Clinical Report: Addressing the Corneal Nerves in DED Care

Overview

Expand on the relationship between DED and corneal nerve dysfunction with specific examples.

Background

Dry eye disease (DED) is a multifactorial condition that significantly impacts patients' ocular health and quality of life. The inflammatory cycle associated with DED can lead to corneal nerve dysfunction, which complicates the management of the disease. Understanding the interplay between DED and corneal nerves is essential for effective diagnosis and treatment.

Data Highlights

No numerical data available in the source material.

Key Findings

Incorporate findings related to chronic DED's impact on ocular health and long-term consequences.

Clinical Implications

Clinicians should prioritize identifying the root causes of DED to implement targeted treatments effectively. A comprehensive approach, including assessing corneal sensitivity, can enhance patient outcomes, especially in cases where initial therapies have failed.

Conclusion

Addressing the complexities of DED, particularly the role of corneal nerves, is vital for improving patient care and outcomes. A tailored treatment strategy that considers the multifactorial nature of DED can lead to better management and quality of life for patients.

References

  1. Beeran Meghpara, MD, Manjool Shah, MD, Ophthalmology Management, 2024 -- Understanding the Difference Between Dry Eye Disease and Neurotrophic Keratitis
  2. Optometric Management, 2019 -- Make the Ocular Surface Healthy
  3. Ophthalmology Management, 2022 -- QUICK HITS
  4. Optometric Management, 2023 -- Treat Dry Eye Disease by Severity
  5. TFOS DEWS III: Executive Summary - ScienceDirect, 2026
  6. In vivo confocal microscopy provides evidence of corneal nerve damage and basal tear film reduction in patients treated with oral isotretinoin | Journal of Translational Medicine, 2025
  7. Okyo Unveils Strong Phase 2 Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
  8. TFOS DEWS III: Executive Summary - ScienceDirect
  9. In vivo confocal microscopy provides evidence of corneal nerve damage and basal tear film reduction in patients treated with oral isotretinoin | Journal of Translational Medicine | Full Text

Original Source(s)

Related Content